Therapy Areas: Oncology
Curocell secures full approval for RIMQARTO to enter CAR-T therapy market
30 April 2026 - Cell therapy company Curocell (KOSDAQ:372320) announced on Thursday that RIMQARTO Inj. (anbalcabtagene autoleucel) has received full regulatory approval from South Korea's Ministr...
European Commission clears first pertuzumab biosimilar in Europe
29 April 2026 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Wednesday that the European Commission has approv...
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance
29 April 2026 - Chinese biopharmaceutical company C-Ray Therapeutics (Chengdu) Co Ltd announced on Tuesday that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has bee...
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
28 April 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for bepirovirsen for pr...
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
28 April 2026 - US pharmaceutical company Xcovery Holdings Inc announced on Monday an agreement with EVERSANA, a provider of commercialisation services to the global life sciences industry, to support...
Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA
28 April 2026 - US pharmaceutical company Jazz Pharmaceuticals plc (Nasdaq:JAZZ) announced on Monday that the US Food and Drug Administration (FDA) has accepted for filing with Priority Review the sup...